Myelodysplastic syndromes treatment options

De novo and secondary myelodysplastic syndromes

Treatment of de novo and secondary myelodysplastic syndromes may include the following:

  • Supportive care with transfusion therapy.
  • High-dose chemotherapy with stem cell transplant using stem cells from a donor.
  • Supportive care with growth factor therapy.
  • Chemotherapy with azacitidine, decitabine or other anticancer drugs.
  • Supportive care with drug therapy.
  • A clinical trial of a new anti-cancer drug.
  • A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor.
  • A clinical trial of a combination of treatments.
  • A clinical trial of growth factor therapy.

Previously treated myelodysplastic syndromes

Treatment of previously treated myelodysplastic syndromes may include the following:

  • High-dose chemotherapy with stem cell transplant using stem cells from a donor.
  • Chemotherapy with azacitidine or decitabine.
  • Supportive care with transfusion therapy, growth factor therapy and/or drug therapy.
  • A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor.
  • A clinical trial of new drug therapy.
  • A clinical trial of a combination of treatments.
  • A clinical trial of growth factor therapy.